The metabolic fate of isotopically labeled trimethylamine-N-oxide (TMAO) in humans

Trimethylamine-N-oxide (TMAO) is associated with chronic disease risk. However, little is known about the metabolic fate of dietary TMAO. This study sought to quantitatively elucidate the metabolic fate of orally consumed TMAO in humans. As part of a crossover feeding study, healthy young men (n=40)...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of nutritional biochemistry 2017-07, Vol.45, p.77-82
Main Authors: Taesuwan, Siraphat, Cho, Clara E., Malysheva, Olga V., Bender, Erica, King, Julia H., Yan, Jian, Thalacker-Mercer, Anna E., Caudill, Marie A.
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Deuterium
Flavin-containing monooxygenase
Humans
Male
Metabolic fate
Methylamines - administration & dosage
Methylamines - blood
Methylamines - pharmacokinetics
Methylamines - urine
Middle Aged
Muscle, Skeletal - metabolism
Oxygenases - genetics
Oxygenases - metabolism
Polymorphism, Genetic
Stable isotope
Trimethylamine
Trimethylamine-N-oxide
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Trimethylamine-N-oxide (TMAO) is associated with chronic disease risk. However, little is known about the metabolic fate of dietary TMAO. This study sought to quantitatively elucidate the metabolic fate of orally consumed TMAO in humans. As part of a crossover feeding study, healthy young men (n=40) consumed 50-mg deuterium-labeled methyl d9-TMAO (d9-TMAO), and enrichments of TMAO and its derivatives were measured in blood for 6 h, urine and stool, as well as skeletal muscle in a subset of men (n=6). Plasma d9-TMAO was detected as early as 15 min, increased until 1 h and remained elevated through the 6-h period. TMAO exhibited an estimated turnover time of 5.3 h, and ~96% of the dose was eliminated in urine by 24 h, mainly as d9-TMAO. No d9-TMAO was detected in feces. Notably, d9-TMAO and d9-trimethylamine were detected in skeletal muscle (n=6) at 6 h, and the enrichment ratio of d9-TMAO to d9-trimethylamine was influenced by a genetic variant in flavin-containing monooxygenase isoform 3 (FMO3 G472A). These results suggest that the absorption of orally consumed TMAO is near complete and does not require processing by gut microbes. TMAO exhibits fast turnover in the circulation with the majority being eliminated in urine within 24 h. A small portion of the dose, however, is taken up by extrahepatic tissue in a manner that appears to be under the influence of FMO3 G472A polymorphism. This trial was registered at clinicaltrials.gov as NCT02558673.
ISSN:0955-2863
1873-4847
DOI:10.1016/j.jnutbio.2017.02.010